CD8A and neoplasm: The 4T1 tumor model displayed expansion and activation of CD4+ T, CD8+ T, and NK cells upon combination treatment with sICAM‐1 and anti‐PD‐1, compared to anti‐PD‐1 therapy alone (Figure 5e).